2.3 Conclusions and Results
According to the findings from serum protein electrophoresis, protein
immunofixation, bone marrow biopsy, and other relevant examinations, a
definitive diagnosis of multiple myeloma was established (high-risk
group, DS stage II, R-ISS stage III). Treatment principles were outlined
as follows: 1. Due to the patient’s young age, targeted therapy for the
underlying disease was initiated promptly, aiming for a deep response
within four cycles, followed by hematopoietic stem cell transplantation.
2. Given the elevated triglycerides, treatment included fenofibrate,
elotuzumab, and plasma exchange therapy. During the treatment process,
after plasma exchange, the patient underwent the PCD regimen,
supplemented with lipid-lowering measures, hydration, alkalization,
liver protection, and symptomatic supportive care. Subsequently, there
was a noticeable improvement in symptoms, leading to discharge.